Indevus in deal with Teva for pagoclone in stuttering
This article was originally published in Scrip
Executive Summary
Indevus Pharmaceuticalshas signed a development and licensing agreement with Teva Pharmaceuticals Industriesfor the exclusive worldwide rights to the novel product, pagoclone, in development as a treatment for persistent stuttering. Under the deal, Teva will reimburse Phase IIb expenses incurred by Indevus, the company said. A previous eight-week Phase II trial showed that pagoclone produced a statistically significant benefit in multiple primary and secondary stuttering endpoints compared with placebo; pagoclone is a novel member of the cyclopyrrolone class of compounds and acts as a gamma-amino butyric acid (GABA) selective receptor modulator. After completion of a successful Phase IIb trial, the agreement provides for Indevus to participate on a 50/50 basis with Teva in the US, sharing development and marketing costs and splitting future profits in addition to receiving milestone payments.